

PTO/SB/25 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING  
REJECTION OVER A PENDING "REFERENCE" APPLICATIONDocket Number (Optional)  
PC31283 (S03376)

In re Application of: Kenton Fedde et al

Application No.: 09/941,206

Filed: 8/28/2001

For: USE OF AN ALDOSTERONE RECEPTOR ANTAGONIST TO IMPROVE COGNITIVE FUNCTION

The owner\*, Pharmacia Corporation, of 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending **reference** Application Number 09/518854, filed on 3/3/2000, as such term is defined in 35 U.S.C. 154 and 173, and as the term of any patent granted on said **reference** application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the **reference** application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of any patent granted on said **reference** application, "as the term of any patent granted on said **reference** application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending **reference** application," in the event that: any such patent: granted on the pending **reference** application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1.  For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2.  The undersigned is an attorney or agent of record. Reg. No. 54,456

Signature

8/18/2005

Date

Christopher W. Slavinsky

Typed or printed name

08/22/2005 SHASSEN1 00000089 191025 09941206

314-274-7008

02 FC:1814 130.00 DA

Telephone Number

- Terminal disclaimer fee under 37 CFR 1.20(d) is included.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).  
Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Pharmacia CorporationApplication No./Patent No.: 09/941,206 Filed/Issue Date: 08/28/2001

Entitled: USE OF AN ALDOSTERONE RECEPTOR ANTAGONIST TO IMPROVE COGNITIVE FUNCTION

Pharmacia Corp., a Corporation  
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1.  the assignee of the entire right, title, and interest; or
2.  an assignee of less than the entire right, title and interest.  
The extent (by percentage) of its ownership interest is \_\_\_\_\_ %

in the patent application/patent identified above by virtue of either:

A  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012724, Frame 0533, or for which a copy thereof is attached.

**OR**

B  A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet.

Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

8/18/2005

Date

Christopher W. Slavinsky314-274-7008

Printed or Typed Name

Telephone Number

Corporate Counsel

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



## United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [FAQ](#) | [Glossary](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)
**PATENT APPLICATION INFORMATION RETRIEVAL****PAIR****FAQ****Help****Feedback****Patent Assignment Abstract of Title****Total Assignments: 1****Application #:** 09456614    **Filing Dt:** 12/08/1999**Patent #:** 6410054**Issue Dt:** 06/25/2002**PCT #:** NONE**Publication #:** NONE**Pub Dt:****Inventors:** SHILPA S. THOSAR, RAJEEV D. GOKHALE, DWAIN S. TOLBERT**Title:** IMMEDIATE RELEASE EPLERENONE COMPOSITIONS**Assignment: 1****Other Links****Reel/Frame:** 010876/0168    **Received:** 06/29/2000**Recorded:**  
06/05/2000**Mailed:**  
08/17/2000**Pages:**  
3**E-Business Center Patents****Conveyance:** ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).**Employee Locator****Assignors:** THOSAR, SHILPA S.**Exec Dt:** 06/01/2000**Class/Subclass GAI Information****GOKHALE, RAJEEV D.****Exec Dt:** 06/01/2000**Information Contacts****TOLBERT, DWAIN S.****Exec Dt:** 06/01/2000**Assignee:** G.D. SEARLE & CO.**P.O. BOX 5110****CHICAGO, ILLINOIS 60680****Correspondent:** EDWARD P. GAMSON, ESQ.  
120 SOUTH RIVERSIDE PLAZA, 22ND FLOOR  
CHICAGO, ILLINOIS 60606

Search Results as of: 7/18/2005 10:39:00 A.M.

**Disclaimer:***Assignment information on the assignment database reflects assignment documents that have been actually recorded.**If the assignment for a patent was not recorded, the name of the assignee on the patent application publication or patent may be different.**If you have any comments or questions concerning the data displayed, contact OPR / Assignments at 703-308-9723*
[HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)



## United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [FAQ](#) | [Glossary](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)
**PATENT APPLICATION INFORMATION RETRIEVAL****PAIR****FAQ****Help****Feedback****Patent Assignment Abstract of Title****Total Assignments: 1****Application #:** 09518854    **Filing Dt:** 03/03/2000**Patent #:** NONE**Issue Dt:****PCT #:** NONE**Publication #:** NONE**Pub Dt:****Inventors:** John Alexander, Barbara Roniker, Subhash Desai**Title:** Triple therapy of angiotensin converting enzyme inhibitor epoxy-steroidal aldosterone antagonist and diuretic or digoxin for treatment of cardiovascular disease**Assignment: 1****Reel/Frame:** 010969/0574    **Received:**  
08/08/2000**Recorded:**  
07/17/2000**Mailed:**  
09/22/2000**Pages:**  
4**Conveyance:** ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).**Assignors:** ALEXANDER, J.C.**Exec Dt:** 06/27/2000

RONIKER, B.

**Exec Dt:** 07/05/2000

DESAI, S.

**Exec Dt:** 06/29/2000**Assignee:** PHARMACIA CORPORATION

5200 OLD ORCHARD ROAD

P.O. BOX 5110

CHICAGO, ILLINOIS 60680

**Correspondent:** PHARMACIA CORPORATION

J. TIMOTHY KEANE

CORPORATE PATENT DEPARTMENT

5200 OLD ORCHARD ROAD

SKOKIE, IL 60077

Search Results as of: 7/18/2005 10:40:41 A.M.


**Disclaimer:***Assignment information on the assignment database reflects assignment documents that have been actually recorded.**If the assignment for a patent was not recorded, the name of the assignee on the patent application publication or patent may be different.**If you have any comments or questions concerning the data displayed, contact OPR / Assignments at 703-308-9723*
[HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)

## CERTIFICATE

The undersigned, Don W. Schmitz, Vice President, Associate General Counsel and Secretary of Pharmacia Corporation (formerly Monsanto Company), hereby certifies that, following the merger transaction between Monsanto Company and Pharmacia & Upjohn Inc. effective as of March 31, 2000, Pharmacia Corporation is the surviving parent of the global organization and that G.D. Searle LLC (formerly G.D. Searle & Co.) is a wholly-owned subsidiary of Pharmacia Corporation.

Signed in Peapack, New Jersey, November 18, 2002.

PHARMACIA CORPORATION



Don W. Schmitz  
Vice President, Associate General Counsel and Secretary

Signed before me this 18<sup>th</sup> day of November 2002.

Notary Public  
EDWARD J. MAY  
A Notary Public Of New Jersey  
My Commission Expires September 20, 2006